美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Scribe Therapeutics, Inc.

21.65

+6.6544.33%

盤後：22.000.3500+1.62%16:20 EDT

成交量：97.93萬

成交額：2,273.25萬

市值：3.50億

市盈率：-8.76

高：25.49

開：25.00

低：21.00

收：15.00

52周最高：25.49

52周最低：21.00

股本：1,618.20萬

流通股本：715.00萬

量比：- -

換手率：13.70%

股息：- -

股息率：- -

每股收益(TTM):-2.4728

淨資產收益率：--

總資產收益率：--

市淨率：-2.21

市盈率(LYR):- -

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

Scribe Therapeutics, Inc.

交易所：

NASDAQ

成立時間：

2017

員工人數：

89

公司地址：

1150 Marina Village Pkwy,Alameda,California,United States

官網：

http://www.scribetx.com

郵編：

94501

電話：

傳真：

- -

簡介：

Scribe Therapeutics, Inc.於2017年6月30日根據特拉華州法律註冊成立。該公司是一家臨床階段的生物技術公司，致力於研發專用的體內CRISPR技術，旨在通過疾病預防和持久的治療干預來延長健康壽命。公司正着力開發其技術，用於治療影響數百萬人的常見疾病，尤其關注那些存在巨大未滿足需求和沉重臨床負擔的流行疾病。公司專註於心血管和代謝疾病，其初期項目旨在解決動脈粥樣硬化性心血管疾病的關鍵驅動因素。公司正在設計基於CRISPR的基因藥物，力求使其具有良好的耐受性、有效性、持久性和可擴展性，從而將治療模式從癥狀驅動的干預和慢性病管理轉變為人群層面的預防。公司的主要候選產品利用其高度工程化的表觀遺傳沉默技術，旨在實現持久有效的LDL-C降低，且不會造成永久性基因改變。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/SCTX/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SCTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCTX\",,,,,undefined,":{"symbol":"SCTX","market":"US","secType":"STK","nameCN":"Scribe Therapeutics, Inc.","latestPrice":21.65,"timestamp":1784923200000,"preClose":15,"halted":0,"volume":979324,"hourTrading":{"tag":"盘后","latestPrice":22,"preClose":21.65,"latestTime":"16:20 EDT","volume":319,"amount":6967.183938,"timestamp":1784924444879,"change":0.35,"changeRate":0.016166,"amplitude":0.050346},"delay":0,"changeRate":0.44333333333333325,"floatShares":7150000,"shares":16182010,"eps":-2.472814,"marketStatus":"盤後交易","change":6.65,"latestTime":"07-24 16:21:13 EDT","open":25,"high":25.49,"low":21,"amount":22732484.9007,"amplitude":0.299333,"askPrice":22.41,"askSize":1,"bidPrice":21.6,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.472814,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1784937600000},"marketStatusCode":4,"adr":0,"listingDate":1784865600000,"exchange":"NASDAQ","adjPreClose":15,"postHourTrading":{"tag":"盘后","latestPrice":22,"preClose":21.65,"latestTime":"16:20 EDT","volume":319,"amount":6967.183938,"timestamp":1784924444879,"change":0.35,"changeRate":0.016166,"amplitude":0.050346},"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCTX\",,,,,undefined,":{"symbol":"SCTX","floatShares":7150000,"roa":"--","roe":"--","lyrEps":0,"shares":16182010,"dividePrice":0,"high":25.49,"amplitude":0.299333,"preClose":15,"low":21,"week52Low":21,"pbRate":"-2.21","psRate":"9.66","week52High":25.49,"institutionHeld":0,"latestPrice":21.65,"committee":0.980198,"eps":-2.472814,"divideRate":0,"volume":979324,"delay":0,"ttmEps":-2.472814,"open":25,"prevYearClose":15,"prevWeekClose":15,"prevMonthClose":15,"prevQuarterClose":15,"fiveDayClose":15,"twentyDayClose":15,"sixtyDayClose":15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SCTX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SCTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SCTX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SCTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SCTX","date":"2026-07-23","current":-6.065964,"percent":1,"low":-6.340558,"twenty":-6.340558,"median":-6.340558,"eighty":-6.340558,"high":-6.340558,"avg":-6.340558,"sd":0,"marketCap":226548140},"quantilePoints":[{"date":"2026-07-23","current":-6.340558,"twenty":-6.340558,"median":-6.340558,"eighty":-6.340558,"marketCap":226548140}],"updateTime":1784882353186},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":642070737,"yearFounded":2017,"employeeNum":89,"address":"1150 Marina Village Pkwy,Alameda,California,United States","zipCode":"94501","officePhone":"510 626 8587"},"stockCompanyDetail":{"websiteUrl":"http://www.scribetx.com","compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":0.0041},{"period":"3month","weight":0.055},{"period":"6month","weight":0.0844},{"period":"1year","weight":0.1885},{"period":"ytd","weight":0.096}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Scribe Therapeutics, Inc.於2017年6月30日根據特拉華州法律註冊成立。該公司是一家臨床階段的生物技術公司，致力於研發專用的體內CRISPR技術，旨在通過疾病預防和持久的治療干預來延長健康壽命。公司正着力開發其技術，用於治療影響數百萬人的常見疾病，尤其關注那些存在巨大未滿足需求和沉重臨床負擔的流行疾病。公司專註於心血管和代謝疾病，其初期項目旨在解決動脈粥樣硬化性心血管疾病的關鍵驅動因素。公司正在設計基於CRISPR的基因藥物，力求使其具有良好的耐受性、有效性、持久性和可擴展性，從而將治療模式從癥狀驅動的干預和慢性病管理轉變為人群層面的預防。公司的主要候選產品利用其高度工程化的表觀遺傳沉默技術，旨在實現持久有效的LDL-C降低，且不會造成永久性基因改變。","exchange":"NASDAQ","name":"Scribe Therapeutics, Inc.","nameEN":"Scribe Therapeutics, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"SCTX\",market:\"US\",,,undefined,":null}}